Skip to main content
. 2021 May 27;20(8):1378–1387. doi: 10.1158/1535-7163.MCT-21-0005

Figure 6.

Figure 6. Comparison of the in vivo efficacy of M3258, ixazomib, and bortezomib in xenograft models. Mice bearing subcutaneous tumors derived from the human multiple myeloma cell lines U266B1 (A), RPMI 8226 (B) or OPM-2 (C) or the human mantle cell lymphoma cell line Granta-519 (D) were treated with vehicle, M3258 (10 mg/kg, once daily orally), bortezomib (0.5 mg/kg, twice weekly intravenously on days 1 and 4) or ixazomib (3 mg/kg, twice weekly orally on days 1 and 4). For A–D, the percentage of T/C values for each treatment and the statistical comparison of the efficacy of each group are shown in Supplementary Table S7.

Comparison of the in vivo efficacy of M3258, ixazomib, and bortezomib in xenograft models. Mice bearing subcutaneous tumors derived from the human multiple myeloma cell lines U266B1 (A), RPMI 8226 (B) or OPM-2 (C) or the human mantle cell lymphoma cell line Granta-519 (D) were treated with vehicle, M3258 (10 mg/kg, once daily orally), bortezomib (0.5 mg/kg, twice weekly intravenously on days 1 and 4) or ixazomib (3 mg/kg, twice weekly orally on days 1 and 4). For A–D, the percentage of T/C values for each treatment and the statistical comparison of the efficacy of each group are shown in Supplementary Table S7.